Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Lampasona

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Therapeutic Drug Monitoring|January 1, 1983
Patient selection for serum gentamicin levelsV Lampasona, R E Crass
American Journal of Hospital Pharmacy|July 1, 1982
Team approach in providing clinical pharmacokinetic servicesR R Maddox, V Lampasona
Topics in Hospital Pharmacy Management|April 11, 1982
Administrative aspects of clinical pharmacokinetic servicesR R Maddox, V Lampasona
Journal of Immunology (Baltimore, Md. : 1950)|September 2, 1998
IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigensE Bonifacio, V Lampasona, P J Bingley
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 28, 2014
New trend in non-invasive prenatal diagnosisM Ferrari, P Carrera, V Lampasona, et al.
Diabetologia|March 29, 2001
ICA12(SOX13) autoantibodies are unlikely to be a useful marker for pre-clinical Type I diabetesV Lampasona, M Scirpoli, E Bosi, et al.
Clinical Pharmacy|January 1, 1983
Decreased serum tobramycin concentrations in patient with renal failureV Lampasona, R E Crass, H D Reines
Diabetologia|June 1, 1996
Islet cell autoantigen 69 antibodies in IDDMS Martin, V Lampasona, M Dosch, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 13, 2006
No evidence of diabetes-specific CD38 (ADP ribosil cyclase/cyclic ADP-ribose hydrolase) autoantibodies by liquid-phase immunoprecipitationV Sordi, V Lampasona, S Cainarca, et al.
Biotechniques|November 1, 1993
Non-radioisotopic typing of human leukocyte antigen class II genes on microplatesR Giorda, V Lampasona, M Kocova, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Therapeutic Drug Monitoring|January 1, 1983
Patient selection for serum gentamicin levelsV Lampasona, R E Crass
American Journal of Hospital Pharmacy|July 1, 1982
Team approach in providing clinical pharmacokinetic servicesR R Maddox, V Lampasona
Topics in Hospital Pharmacy Management|April 11, 1982
Administrative aspects of clinical pharmacokinetic servicesR R Maddox, V Lampasona
Journal of Immunology (Baltimore, Md. : 1950)|September 2, 1998
IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigensE Bonifacio, V Lampasona, P J Bingley
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 28, 2014
New trend in non-invasive prenatal diagnosisM Ferrari, P Carrera, V Lampasona, et al.
Diabetologia|March 29, 2001
ICA12(SOX13) autoantibodies are unlikely to be a useful marker for pre-clinical Type I diabetesV Lampasona, M Scirpoli, E Bosi, et al.
Clinical Pharmacy|January 1, 1983
Decreased serum tobramycin concentrations in patient with renal failureV Lampasona, R E Crass, H D Reines
Diabetologia|June 1, 1996
Islet cell autoantigen 69 antibodies in IDDMS Martin, V Lampasona, M Dosch, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 13, 2006
No evidence of diabetes-specific CD38 (ADP ribosil cyclase/cyclic ADP-ribose hydrolase) autoantibodies by liquid-phase immunoprecipitationV Sordi, V Lampasona, S Cainarca, et al.
Biotechniques|November 1, 1993
Non-radioisotopic typing of human leukocyte antigen class II genes on microplatesR Giorda, V Lampasona, M Kocova, et al.
Pageof 6